Chloe Anthias

Sutton Upon Derwent, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: June 16, 2026

Facilitation of Related Donor Hematopoietic Stem Cell Donation by Unrelated Donor Registries: Recommendations from the World Marrow Donor Association.

Facilitation of Related Donor Hematopoietic Stem Cell Donation by Unrelated Donor Registries: Recommendations from the World Marrow Donor Association.

Journal: Transplantation and cellular therapy

Published: May 14, 2026

World Marrow Donor Association Statement on the Use of Plerixafor in Healthy Donors.

World Marrow Donor Association Statement on the Use of Plerixafor in Healthy Donors.

Journal: Transplantation and cellular therapy

Published: January 10, 2026

Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation.

Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation.

Journal: Blood advances

Published: October 01, 2025

Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.

Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.

Journal: Blood advances

Published: October 01, 2025

Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association.

Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association.

Journal: Transplantation and cellular therapy

Published: September 03, 2025

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.

Journal: Immunotherapy

Published: May 08, 2025

Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation.

Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation.

Journal: Blood advances

Published: January 17, 2025

UK consensus statement on the use of plerixafor in healthy stem cell donors.

UK consensus statement on the use of plerixafor in healthy stem cell donors.

Journal: British journal of haematology

Published: November 18, 2024

Hematopoietic Stem Cell (HSC) Graft Cryopreservation Effects on Outcomes of Patients with Hematologic Malignancies: the Multicenter United Kingdom Experience During the COVID-19 Pandemic.

Hematopoietic Stem Cell (HSC) Graft Cryopreservation Effects on Outcomes of Patients with Hematologic Malignancies: the Multicenter United Kingdom Experience During the COVID-19 Pandemic.

Journal: Transplantation and cellular therapy

Published: October 25, 2024

Re-vaccination against SARS-CoV-2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates.

Re-vaccination against SARS-CoV-2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates.

Journal: British journal of haematology

Published: July 09, 2024

Facilitating the ethical sourcing of donor hematopoietic stem cells for cell and gene therapy research and development.

Facilitating the ethical sourcing of donor hematopoietic stem cells for cell and gene therapy research and development.

Journal: Regenerative medicine

Published: June 18, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026